Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 1
2010 2
2011 2
2012 1
2014 2
2015 4
2016 2
2017 8
2018 7
2019 9
2020 10
2021 11
2022 3
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean dongchuan jiang (309 results)?
Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.
Li JY, Jing R, Wei H, Wang M, Xiaowei Q, Liu H, Jian L, Ou JH, Jiang WH, Tian FG, Sheng Y, Li HY, Xu H, Zhang RS, Guan AH, Liu K, Jiang HC, Ren Y, He JJ, Huang W, Liao N, Cai X, Ming J, Ling R, Xu Y, Hu CY, Zhang J, Guo B, Ouyang L, Shuai P, Liu Z, Zhong L, Zeng Z, Zhang T, Xuan Z, Tan X, Liang J, Pan Q, Chen L, Zhang F, Fan LJ, Zhang Y, Yang X, BoLi J, Chen C, Jiang J. Li JY, et al. Int J Cancer. 2019 Jan 15;144(2):281-289. doi: 10.1002/ijc.31601. Epub 2018 Nov 8. Int J Cancer. 2019. PMID: 29752822 Free article.
Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapy.
Maimaitiaili A, Chen H, Xie P, Liu Z, Ling R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, Mao D, Yu Z, Liu Y, Fu P, Wang J, Jiang H, Zhao Z, Tian X, Cao Z, Wu K, Song A, Jin F, He J, Fan Z, Zhang H. Maimaitiaili A, et al. Among authors: jiang h. J Cancer Res Clin Oncol. 2023 Sep;149(11):8769-8778. doi: 10.1007/s00432-023-04817-9. Epub 2023 May 2. J Cancer Res Clin Oncol. 2023. PMID: 37129606
Association of a complete breast cancer pathologic response with axillary lymph node metastasis via neoadjuvant chemotherapy: Results from the CSBrS-012 study.
Ma L, Gao P, Liu Z, Jiao D, Ling R, Xiao J, Zhao Y, Wang Y, Yang H, Liu Y, Liu K, Zhang J, Li G, Mao D, Deng Y, He J, Amina M, Yu Z, Fei W, Liu Y, Fu P, Yao M, Wang J, Zhu L, Jiang H, Zhao Z, Tian X, Cao Z, Ma X, Wu K, Fu S, Song A, Wang Y, Feng J, Fan Z. Ma L, et al. Among authors: jiang h. Chin Med J (Engl). 2023 Oct 25. doi: 10.1097/CM9.0000000000002849. Online ahead of print. Chin Med J (Engl). 2023. PMID: 37882089 No abstract available.
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012).
Chen H, Maimaitiaili A, Liu Z, Ling R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, Mao D, Yu Z, Liu Y, Fu P, Wang J, Jiang H, Zhao Z, Tian X, Cao Z, Wu K, Song A, Jin F, He J, Fan Z, Zhang H. Chen H, et al. Among authors: jiang h. Ther Adv Med Oncol. 2023 Feb 28;15:17588359231156146. doi: 10.1177/17588359231156146. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36891484 Free PMC article.
Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
Guo X, Zhang J, Gong X, Wang J, Dai H, Jiao D, Ling R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, Mao D, He J, Yu Z, Liu Y, Fu P, Wang J, Jiang H, Zhao Z, Tian X, Cao Z, Wu K, Song A, Jin F, Fan Z, Liu Z. Guo X, et al. Among authors: jiang h. Breast. 2024 Feb;73:103671. doi: 10.1016/j.breast.2024.103671. Epub 2024 Jan 5. Breast. 2024. PMID: 38277714 Free PMC article.
Flexible nanofiber sensor for low-concentration hydrogen detection.
Zhang L, Jiang H, Zhang J, Huang Y, Tian J, Deng X, Zhao X, Zhang W. Zhang L, et al. Among authors: jiang h. Nanotechnology. 2020 Jan 3;31(1):015504. doi: 10.1088/1361-6528/ab435f. Epub 2019 Sep 11. Nanotechnology. 2020. PMID: 31509818
Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial.
Yang Y, He Y, Fan Z, Chen X, Liu Y, Zhang C, Jiang H, Wang X, Wang X, Xie F, Wang S, Luo B, Kang H, Wang T, Jiang Z, Yuan P, Xu B, Xu L, Liu Y, Li J, Xie Y, Wang T, Ouyang T. Yang Y, et al. Among authors: jiang h. NPJ Breast Cancer. 2023 Jun 21;9(1):54. doi: 10.1038/s41523-023-00553-y. NPJ Breast Cancer. 2023. PMID: 37344451 Free PMC article.
70 results